Protein kinase C isozymes as therapeutic targets for treatment of human cancers

Research output: Contribution to journalArticle

29 Scopus citations


PKC isozymes play specific, non-redundant functional roles in numerous cellular processes, including proliferation, differentiation, cellular invasion and apoptosis. We have determined that PKCβII and PKCι are both critical pro-carcinogenic genes involved in multiple human cancers. PKCι (PRKCI) is a bonafide human oncogene, the first PKC isozyme that can be so classified. Both PKCβII and PKCι are legitimate therapeutic targets to which novel targeted therapy has been successfully developed and is being evaluated clinically.

Original languageEnglish (US)
Pages (from-to)166-178
Number of pages13
JournalAdvances in Enzyme Regulation
Issue number1
StatePublished - Sep 15 2008


ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this